A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03673501 |
Recruitment Status : Unknown
Verified January 2021 by Deciphera Pharmaceuticals LLC.
Recruitment status was: Active, not recruiting
First Posted : September 17, 2018
Last Update Posted : January 6, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Gastrointestinal Stromal Tumors | Drug: DCC-2618 Drug: Sunitinib | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 426 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib |
Actual Study Start Date : | February 11, 2019 |
Estimated Primary Completion Date : | June 2021 |
Estimated Study Completion Date : | March 2022 |

Arm | Intervention/treatment |
---|---|
Experimental: DCC-2618
150 mg QD DCC-2618
|
Drug: DCC-2618
Oral KIT/PDGFRA kinase inhibitor
Other Name: ripretinib |
Active Comparator: sunitinib
50 mg QD sunitinib
|
Drug: Sunitinib
Oral receptor tyrosine kinase (RTK) inhibitor
Other Name: Sutent |
- Progression free survival (PFS) [ Time Frame: 30 months ]PFS Based on independent radiologic review using modified RECIST
- Objective response rate (ORR) [ Time Frame: 30 months ]Objective response rate as determined by confirmed CR + confirmed PR by independent radiologic review
- Overall Survival (OS) [ Time Frame: 30 months ]Measure of overall survival

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients ≥ 18 years of age at the time of informed consent.
- Histologic diagnosis of GIST and must be able to provide an archival tumor tissue sample, otherwise, a fresh biopsy is required.
- Molecular pathology report must be available. If molecular pathology report is not available or insufficient, an archival tumor tissue sample or fresh biopsy is required for mutation status confirmation by the central laboratory prior to randomization.
- Patients must have progressed on imatinib or have documented intolerance to imatinib.
- Eastern Cooperative Oncology Group (ECOG) PS of ≤ 2 at screening.
- Female patients of childbearing potential must have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test at screening and negative pregnancy test at Cycle 1 Day 1 prior to the first dose of study drug.
- Patients of reproductive potential must agree to follow the contraception requirements outlined in the study protocol.
- Patients must have at least 1 measurable lesion according to mRECIST Version 1.1 (non nodal lesions must be ≥ 1.0 cm in the long axis or ≥ double the slice thickness in the long axis) within 21 days prior to the first dose of study drug.
- Adequate organ function and bone marrow reserve as indicated by the central laboratory assessments performed at screening.
- Resolution of all toxicities from prior therapy to ≤ Grade 1 (or patient baseline) within 1 week prior to the first dose of study drug (excluding alopecia and ≤ Grade 3 clinically asymptomatic lipase, amylase, and creatine phosphokinase [CPK] laboratory abnormalities).
- The patient is capable of understanding and complying with the protocol and the patient has signed the informed consent document. Signed informed consent form (ICF) must be obtained before any study-specific procedures are performed and the patient must agree to not participate in any other interventional clinical trial while on treatment in this clinical trial. Participation in a noninterventional study (including observational studies) is permitted.
Exclusion Criteria:
- Treatment with any other line of therapy in addition to imatinib for advanced GIST. Imatinib-containing combination therapy in the first-line setting is not allowed.
- Patients with a prior or concurrent malignancy whose natural history or treatment have the potential to interfere with the safety or efficacy assessment of this clinical trial are not eligible.
- Patient has known active central nervous system metastases.
- New York Heart Association class II-IV heart disease, myocardial infarction within 6 months of cycle 1 day 1, active ischemia or any other uncontrolled cardiac condition such as angina pectoris, clinically significant cardiac arrhythmia requiring therapy, uncontrolled hypertension or congestive heart failure.
- Left ventricular ejection fraction (LVEF) < 50% at screening.
- Arterial thrombotic or embolic events such as cerebrovascular accident (including ischemic attacks) or hemoptysis within 6 months before the first dose of study drug.
- Venous thrombotic events (e.g. deep vein thrombosis) or pulmonary arterial events (e.g. pulmonary embolism) within 1 month before the first dose of study drug. Patients on stable anticoagulation therapy for at least one month are eligible.
- 12-lead ECG demonstrating QT interval corrected (QTc) by Fridericia's formula > 450 ms in males or > 470 ms in females at screening or history of long QTc syndrome
- Use of known substrates or inhibitors of BCRP transporters within 14 days or 5 x the half-life (whichever is longer) prior to the first dose of study drug.
- Major surgeries (e.g. abdominal laparotomy) within 4 weeks of the first dose of study drug. All major surgical wounds must be healed and free of infection or dehiscence before the first dose of study drug.
- Any other clinically significant comorbidities.
- Known human immunodeficiency virus or hepatitis C infection only if the patient is taking medications that are excluded per protocol, active hepatitis B, or active hepatitis C infection.
- If female, the patient is pregnant or lactating.
- Known allergy or hypersensitivity to any component of the study drug.
-
Gastrointestinal abnormalities including but not limited to:
- inability to take oral medication
- malabsorption syndromes
- requirement for intravenous (IV) alimentation
- Any active bleeding excluding hemorrhoidal or gum bleeding.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03673501

United States, Arizona | |
Mayo Clinic Scottsdale | |
Scottsdale, Arizona, United States, 85259 | |
United States, California | |
University of California San Diego Medical Center | |
La Jolla, California, United States, 92103 | |
UCLA Hematology Oncology Center - Main Site | |
Los Angeles, California, United States, 90024 | |
Stanford Medicine | |
Stanford, California, United States, 94305 | |
United States, Colorado | |
University of Colorado Hospital - Anschutz Cancer Pavillion | |
Aurora, Colorado, United States, 80045 | |
Rocky Mountain Cancer Centers | |
Denver, Colorado, United States, 80220 | |
United States, Connecticut | |
Smilow Cancer Hospital at Yale | |
New Haven, Connecticut, United States, 06511 | |
United States, District of Columbia | |
Washington Cancer Institute at MedStar Washington Hospital Center | |
Washington, District of Columbia, United States, 20010 | |
United States, Florida | |
Mayo Clinic Florida | |
Jacksonville, Florida, United States, 32224 | |
Sylvester Comprehensive Cancer Center | |
Miami, Florida, United States, 33136 | |
Miami Cancer Institute at Baptist Health, Inc. | |
Miami, Florida, United States, 33176 | |
Orlando Health UF Health Cancer Center | |
Orlando, Florida, United States, 32806 | |
Moffitt Cancer Center | |
Tampa, Florida, United States, 33612 | |
United States, Georgia | |
Winship Cancer Institute | |
Atlanta, Georgia, United States, 30332 | |
Georgia Cancer Specialists | |
Sandy Springs, Georgia, United States, 30342 | |
United States, Illinois | |
Northwestern Memorial Hospital | |
Chicago, Illinois, United States, 60611 | |
University of Chicago Medical Center | |
Chicago, Illinois, United States, 60637 | |
United States, Indiana | |
IU Simon Cancer Center | |
Indianapolis, Indiana, United States, 46202 | |
United States, Iowa | |
University of Iowa Hospital and Clinics | |
Iowa City, Iowa, United States, 52242 | |
United States, Kentucky | |
Norton Cancer Institute, Audubon Hospital Campus | |
Louisville, Kentucky, United States, 40241 | |
United States, Maryland | |
Johns Hopkins Hospital | |
Baltimore, Maryland, United States, 21287 | |
United States, Massachusetts | |
Dana Farber Cancer Institute | |
Boston, Massachusetts, United States, 02215 | |
United States, Michigan | |
Henry Ford Health System | |
Detroit, Michigan, United States, 48202 | |
United States, Minnesota | |
University of Minnesota Medical Center-Fairview | |
Minneapolis, Minnesota, United States, 55455 | |
Mayo Clinic | |
Rochester, Minnesota, United States, 55905 | |
United States, Missouri | |
Washington University School of Medicine - Siteman Cancer Center | |
Saint Louis, Missouri, United States, 63110 | |
United States, New Jersey | |
Rutgers Cancer Institute | |
New Brunswick, New Jersey, United States, 08901 | |
United States, New York | |
Montefiore Medical Center-Montefiore Medical Park | |
Bronx, New York, United States, 10467 | |
Roswell Park Cancer Institute | |
Buffalo, New York, United States, 43606 | |
The Monter Cancer Center | |
Lake Success, New York, United States, 11042 | |
Memorial Sloan Kettering Cancer Center | |
New York, New York, United States, 10065 | |
United States, North Carolina | |
Duke University Medical Center | |
Durham, North Carolina, United States, 27710 | |
United States, Ohio | |
The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Solove Research Institute | |
Columbus, Ohio, United States, 43210 | |
University of Toledo | |
Toledo, Ohio, United States, 43606 | |
United States, Oklahoma | |
Stephenson Cancer Center | |
Oklahoma City, Oklahoma, United States, 73104 | |
United States, Oregon | |
Oregon Health & Science University Center for Health and Healing | |
Portland, Oregon, United States, 97239 | |
United States, Pennsylvania | |
Fox Chase Cancer Center | |
Philadelphia, Pennsylvania, United States, 19111 | |
United States, Tennessee | |
Henry-Joyce Cancer Clinic | |
Nashville, Tennessee, United States, 37232 | |
United States, Texas | |
Texas Oncology-Baylor Charles A. Sammons Cancer Center | |
Dallas, Texas, United States, 75246 | |
University of Texas MD Anderson Cancer Center | |
Houston, Texas, United States, 77030 | |
United States, Virginia | |
Virginia Commonwealth University Massey Cancer Center | |
Richmond, Virginia, United States, 23298 | |
United States, Washington | |
University of Washington Medical Center | |
Seattle, Washington, United States, 98195 | |
United States, Wisconsin | |
Froedtert Hospital-Medical College of Wisconsin | |
Milwaukee, Wisconsin, United States, 53226 | |
Argentina | |
Sanatorio Allende | |
Córdoba, Cordoba, Argentina, X5000JHQ | |
Instituto Medicao Especializado Alexander Fleming | |
Buenos Aires, Argentina | |
Australia, New South Wales | |
Border Medical Oncology Research Unit | |
Albury, New South Wales, Australia | |
Prince of Wales Hospital | |
Randwick, New South Wales, Australia, 2031 | |
Australia, Queensland | |
Princess Alexandra Hospital | |
Woolloongabba, Queensland, Australia | |
Australia, South Australia | |
Ashford Cancer Centre Research | |
Kurralta Park, South Australia, Australia, 5037 | |
Ashford Cancer Centre Research | |
Kurralta Park, South Australia, Australia | |
Australia, Victoria | |
The Alfred Hospital | |
Melbourne, Victoria, Australia, 3004 | |
Australia | |
Princess Alexandara Hospital | |
Woolloongabba, Australia | |
Belgium | |
Institut Jules Bordet | |
Bruxelles, Belgium | |
UZ Leuven | |
Leuven, Belgium | |
Canada, Alberta | |
Cross Cancer Institute | |
Edmonton, Alberta, Canada | |
Canada, Manitoba | |
CancerCare Manitoba | |
Winnipeg, Manitoba, Canada | |
Canada, Ontario | |
Juravinski Cancer Centre | |
Hamilton, Ontario, Canada | |
The Ottawa Hospital Cancer Centre | |
Ottawa, Ontario, Canada | |
Princess Margaret Cancer Centre | |
Toronto, Ontario, Canada, M5G 2C1 | |
Canada | |
Hopital Maisonneuve-Rosemont | |
Québec, Canada | |
Chile | |
Clinica San Carlos de Apoquindo Red Salud UC Christs | |
Santiago, Chile | |
Czechia | |
Fakultni nemocnice v Motole | |
Prague, Czechia | |
France | |
Institut Bergonnié | |
Bordeaux, France | |
Centre Georges François Leclerc | |
Dijon, France | |
Centre Oscar Lambret | |
Lille Cedex, France | |
Centre Léon Bérard | |
Lyon, France | |
Hopital La Timone | |
Marseille, France | |
IPC | |
Marseille, France | |
IGR | |
Paris, France | |
CHU Poitiers-Hopital la Miletrie | |
Poitiers, France | |
ICO - Site René Gauducheau | |
Saint Herblain, France | |
Germany | |
HELIOS Klinikum Berlin-Buch | |
Berlin, Germany | |
Technische Universitat Dresden | |
Dresden, Germany | |
West German Cancer Center | |
Essen, Germany | |
Hungary | |
Magyar Honvedseg Egeszsegugyi Kozpont | |
Budapest, Hungary | |
Debreceni Egyetem | |
Debrecen, Hungary | |
Israel | |
Shamir Medical Center (Assaf Harofeh) | |
Be'er Ya'akov, Israel | |
Rabin Medical Cente | |
Petah Tikva, Israel | |
Tel-Aviv Sourasky Medical Center | |
Tel Aviv, Israel | |
Italy | |
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi | |
Bologna, Italy | |
stituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori | |
Meldola, Italy | |
Fondazione IRCCS Istituto Nazionale dei Tumori | |
Milan, Italy | |
IOV - Istituto Oncologico Veneto IRCCS | |
Padova, Italy | |
Universita degli Studi di Palermo | |
Palermo, Italy | |
Università Campus Bio-Medico di Roma | |
Rome, Italy | |
Korea, Republic of | |
Asan Medical Center | |
Seoul, Korea, Republic of | |
Samsung Medical Center | |
Seoul, Korea, Republic of | |
Seoul National University Hospital | |
Seoul, Korea, Republic of | |
Ajou University Hospital | |
Suwon, Korea, Republic of | |
Netherlands | |
Antoni van Leeuwenhoek | |
Amsterdam, Netherlands | |
The Netherlands Cancer Institute | |
Amsterdam, Netherlands | |
University Medical Center Groningen | |
Groningen, Netherlands | |
Leiden University Medical Centre | |
Leiden, Netherlands | |
Norway | |
Oslo University Hospital | |
Oslo, Norway | |
Poland | |
Centrum Onkologii-Instytut im. M. Sklodowskiej Curie | |
Warsaw, Poland | |
Singapore | |
National Cancer Centre | |
Singapore, Singapore, 169610 | |
Spain | |
Hospital de la Santa Creu i Sant Pau | |
Barcelona, Spain | |
Hospital Universitari Vall d'Hebron | |
Barcelona, Spain | |
Hospital de Basurto | |
Bilbao, Spain | |
Hospital Universitario 12 de Octubre | |
Madrid, Spain | |
Hospital Universitario Clinico San Carlos | |
Madrid, Spain | |
Hospital Universitario HM Madrid Sanchinarro | |
Madrid, Spain | |
Hospital Universitario La Paz | |
Madrid, Spain | |
Hospital Universitario Ramon y Cajal | |
Madrid, Spain | |
Hospital Clinico Universitario Virgen de la Victoria | |
Malaga, Spain | |
Hospital Universitario Virgen del Rocio | |
Sevilla, Spain | |
Instituto Valenciano de Oncología, | |
Valencia, Spain | |
Complejo Hospitalario Universitario de Vigo | |
Vigo, Spain | |
Sweden | |
Karolinska universitetssjukhuset | |
Solna, Sweden | |
Switzerland | |
Centre Hospitalier Universitaire Vaudois, Fondation du Centre Pluridisciplinaire d'Oncologi | |
Lausanne, Switzerland | |
Universitaetsspital Zuerich, Klinik fuer Onkologie | |
Zurich, Switzerland | |
Taiwan | |
Chang Gung Memorial Hospital | |
Linkou, Taoyuan County, Taiwan | |
Kaohsiung Chang Gung Memorial Hospital, | |
Kaohsiung, Taiwan | |
China Medical University Hospital | |
Taichung, Taiwan | |
National Chen Kung University Hospital | |
Tainan, Taiwan | |
Taipei Veterans General Hospital | |
Taipei, Taiwan | |
United Kingdom | |
Beatson West of Scotland Cancer Centre | |
Glasgow, United Kingdom | |
St James's University Hospital | |
Leeds, United Kingdom | |
Royal Marsden Hospital - Fulham | |
London, United Kingdom | |
University College London Hospitals | |
London, United Kingdom | |
Weston Park Hospital | |
Sheffield, United Kingdom |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Deciphera Pharmaceuticals LLC |
ClinicalTrials.gov Identifier: | NCT03673501 |
Other Study ID Numbers: |
DCC-2618-03-002 |
First Posted: | September 17, 2018 Key Record Dates |
Last Update Posted: | January 6, 2021 |
Last Verified: | January 2021 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Gastrointestinal Stromal Tumors Neoplasms, Connective Tissue Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Digestive System Diseases Gastrointestinal Diseases Sunitinib |
Antineoplastic Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |